Entegris (NASDAQ:ENTG – Get Free Report) issued its quarterly earnings data on Thursday. The semiconductor company reported $0.84 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.07, Zacks reports. Entegris had a net margin of 7.13% and a return on equity of 12.24%. Entegris updated its Q1 2025 guidance to 0.640-0.710 EPS.
Entegris Trading Up 5.6 %
Shares of Entegris stock opened at $109.76 on Friday. The firm has a market capitalization of $16.57 billion, a PE ratio of 72.69, a price-to-earnings-growth ratio of 1.38 and a beta of 1.24. The company’s fifty day moving average price is $103.33 and its two-hundred day moving average price is $107.34. Entegris has a 52-week low of $94.92 and a 52-week high of $147.57. The company has a debt-to-equity ratio of 1.14, a current ratio of 2.92 and a quick ratio of 1.83.
Entegris Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 19th. Shareholders of record on Wednesday, January 29th will be paid a dividend of $0.10 per share. The ex-dividend date of this dividend is Wednesday, January 29th. This represents a $0.40 dividend on an annualized basis and a yield of 0.36%. Entegris’s dividend payout ratio is currently 26.49%.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on ENTG
Entegris Company Profile
Entegris, Inc develops, manufactures, and supplies microcontamination control products, specialty chemicals, and advanced materials handling solutions in North America, Taiwan, China, South Korea, Japan, Europe, and Southeast Asia. It operates in three segments: Materials Solutions (MS); Microcontamination Control (MC); and Advanced Materials Handling (AMH).
Featured Stories
- Five stocks we like better than Entegris
- Most Volatile Stocks, What Investors Need to Know
- Broadcom’s Bull Run: Time to Jump In?
- Investing in the High PE Growth Stocks
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- What is a Low P/E Ratio and What Does it Tell Investors?
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
Receive News & Ratings for Entegris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entegris and related companies with MarketBeat.com's FREE daily email newsletter.